Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecularly guided therapy versus platinum chemotherapy in cancer of unknown primary after platinum induction
2017-003040-20Phase 2Unknown
- Sponsor
- Roche
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of atezolizumab in cancer of unknown primary (CUP) (2 arms), sponsored by Roche. Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
atezolizumab
03
Conditions
cancer of unknown primary (CUP)
Beyond the preview
Go deeper on 2017-003040-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003040-20.